These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 20457618)

  • 1. Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression.
    Bobola MS; Kolstoe DD; Blank A; Silber JR
    Mol Cancer Ther; 2010 May; 9(5):1208-18. PubMed ID: 20457618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
    Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
    J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.
    Moen EL; Stark AL; Zhang W; Dolan ME; Godley LA
    Mol Cancer Ther; 2014 May; 13(5):1334-44. PubMed ID: 24568970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
    Wu Q; Berglund AE; Macaulay RJ; Etame AB
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
    Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
    Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MGMT inhibition regulates radioresponse in GBM, GSC, and melanoma.
    Yun HS; Kramp TR; Palanichamy K; Tofilon PJ; Camphausen K
    Sci Rep; 2024 May; 14(1):12363. PubMed ID: 38811596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MGMT gene promoter methylation in pediatric glioblastomas.
    Srivastava A; Jain A; Jha P; Suri V; Sharma MC; Mallick S; Puri T; Gupta DK; Gupta A; Sarkar C
    Childs Nerv Syst; 2010 Nov; 26(11):1613-8. PubMed ID: 20585787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
    Kohsaka S; Wang L; Yachi K; Mahabir R; Narita T; Itoh T; Tanino M; Kimura T; Nishihara H; Tanaka S
    Mol Cancer Ther; 2012 Jun; 11(6):1289-99. PubMed ID: 22532597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.
    Struve N; Binder ZA; Stead LF; Brend T; Bagley SJ; Faulkner C; Ott L; Müller-Goebel J; Weik AS; Hoffer K; Krug L; Rieckmann T; Bußmann L; Henze M; Morrissette JJD; Kurian KM; Schüller U; Petersen C; Rothkamm K; O Rourke DM; Short SC; Kriegs M
    Oncogene; 2020 Apr; 39(15):3041-3055. PubMed ID: 32066879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
    Kitange GJ; Mladek AC; Carlson BL; Schroeder MA; Pokorny JL; Cen L; Decker PA; Wu W; Lomberk GA; Gupta SK; Urrutia RA; Sarkaria JN
    Clin Cancer Res; 2012 Aug; 18(15):4070-9. PubMed ID: 22675172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
    Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A
    J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
    Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
    Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.
    Chahal M; Xu Y; Lesniak D; Graham K; Famulski K; Christensen JG; Aghi M; Jacques A; Murray D; Sabri S; Abdulkarim B
    Neuro Oncol; 2010 Aug; 12(8):822-33. PubMed ID: 20179017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
    Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH
    Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
    Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
    J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.
    Gilbert MR; Wang M; Aldape KD; Stupp R; Hegi ME; Jaeckle KA; Armstrong TS; Wefel JS; Won M; Blumenthal DT; Mahajan A; Schultz CJ; Erridge S; Baumert B; Hopkins KI; Tzuk-Shina T; Brown PD; Chakravarti A; Curran WJ; Mehta MP
    J Clin Oncol; 2013 Nov; 31(32):4085-91. PubMed ID: 24101040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.